Connect
A woman with TGCT kneeling down with "IMPROVED FUNCTION" written on her leg

Vimseltinib is NCCN CATEGORY 1 PREFERRED
IN TGCTGo
beyond
tumor
response
With proven symptomatic and functional improvements2

In adults with symptomatic TGCT when surgery will potentially cause worsening functional limitation or severe morbidity2

  • Robust tumor response: 40% ORR by RECIST with ROMVIMZA vs 0% with placebo2
  • Improvements in active range of motion and patient-reported improvements in physical function* and worst pain2
  • No REMS program required2

*Improved function is defined as an improvement in PROMIS-PF, which measures a patient’s ability to do a range of daily activities.3,4

NCCN=National Comprehensive Cancer Network® (NCCN®); ORR=objective response rate; PROMIS-PF=Patient-Reported Outcomes Measurement Information System Physical Function (TGCT-specific); RECIST v1.1= Response Evaluation Criteria in Solid Tumors version 1.1; REMS=Risk Evaluation and Mitigation Strategy; TGCT=tenosynovial giant cell tumor.

A clipboard with a checklist and a writing utensil

See how ROMVIMZA was studied

Explore efficacy
Two gears

Discover how ROMVIMZA works

A shield with a checkmark on it

Explore ROMVIMZA's safety profile

Hero

Read the
MOTION study

Visit The Lancet for a summary of the pivotal trial, comparing vimseltinib with placebo in the treatment of TGCT.

Link to abstract
Deciphera AccessPoint logoDeciphera AccessPoint logo

Help your patients get started on ROMVIMZA

Enroll your patient
References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed May 5, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 2. ROMVIMZA [package insert]. Waltham, MA: Deciphera Pharmaceuticals, LLC. 3. Gelderblom H, Bhadri V, Stacchiotti S, et al. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;403(10445):2709-2719. 4. Gelderblom H, Bhadri V, Stacchiotti S, et al. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;403(10445)(suppl):1-124.
Deciphera Pharmaceuticals logo
Contact Usdeciphera.comTerms of UsePrivacy Policy

© 2025 Deciphera Pharmaceuticals, LLC. The following are registered trademarks of Deciphera Pharmaceuticals, LLC: DECIPHERA and Deciphera logo. The following are trademarks of Deciphera Pharmaceuticals, LLC: ROMVIMZA, ROMVIMZA logo, Deciphera AccessPoint, and Deciphera AccessPoint logo. All rights reserved. DCPH-P02201 05/25